Earlier and more accurate detection combined with better monitoring of cancer or pre-cancer conditions are improving patient outcomes for serious health conditions. Our team of highly qualified researchers and engineers is working on solutions realizing that goal.

The incidence of cancer is expected to rise a further 57 % in the next two decades. The Company is emerging as a rapidly growing disruptive force in the multi-billion dollar global histology and cytology systems marketplace while positioned to build significant shareholder value.